Teva Pharmaceutical Industries (NYSE:TEVA) EVP Christine Fox Sells 21,258 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the completion of the transaction, the executive vice president directly owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Christine Fox also recently made the following trade(s):

• On Thursday, March 5th, Christine Fox sold 7,924 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $31.67, for a total value of $250,953.08.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded up $0.41 during trading on Monday, reaching $35.36. The company had a trading volume of 7,444,270 shares, compared to its average volume of 8,293,405. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The stock has a market capitalization of $40.65 billion, a PE ratio of 26.58, a price-to-earnings-growth ratio of 3.23 and a beta of 0.86. The stock has a 50-day moving average price of $31.15 and a two-hundred day moving average price of $29.46. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion during the quarter. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.6 earnings per share for the current year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $25,000. Allworth Financial LP grew its position in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares during the period. Grove Bank & Trust grew its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares during the period. EverSource Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its position in Teva Pharmaceutical Industries by 567.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after acquiring an additional 1,134 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. The Goldman Sachs Group lifted their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Truist Financial lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday. Scotiabank lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Finally, Barclays lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.56.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.